Excluded from performance statistics: the forecast was created after its scoring window began (look-ahead bias). Historical results below are retained for audit only.
Asked Sep 8, 11:13 PM EDT (after hours). GPT-5.6 Sol, Muse Spark 1.1, Gemini 1.5 Pro, Grok 4.5, Gemini 3 Pro and Claude Opus 5 answered the same standard prompt independently. Window: 2026-09-08 to 2026-09-09 (1 trading session). Benchmark: SPY.
Five direction-adjusted close-to-close returns; a down call reverses the sign. The score is the mean signed return, without subtracting the benchmark. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that moved the way it was called.
| Model | Correct | Hit rate | Return | SPY | Directional return |
|---|---|---|---|---|---|
| GPT-5.6 Sol | 3/5 | 60.00% | 0.43% | -0.46% | 0.43% |
| Muse Spark 1.1 | 1/5 | 20.00% | -2.61% | -0.46% | -2.61% |
| Gemini 1.5 Pro | 2/5 | 40.00% | -1.90% | -0.46% | -1.90% |
| Grok 4.5 | 4/5 | 80.00% | 0.41% | -0.46% | 0.41% |
| Gemini 3 Pro | 3/5 | 60.00% | -0.59% | -0.46% | -0.59% |
| Claude Opus 5 | 2/5 | 40.00% | -0.34% | -0.46% | -0.34% |
GPT-5.6 Sol
View full picks and reasoning
September 8 produced unusually large single-stock dispersion while the S&P 500 declined 0.58%. The strongest movers were concentrated in biotechnology, AI infrastructure, optical networking and index-rebalancing catalysts, while healthcare contained several severe decliners. For the September 9 session, I favor continuation where the source-session move was supported by genuinely new fundamental information, but reversal where the move was primarily sympathetic or where the initial reaction appears disproportionate. Prices, daily changes and market capitalizations were cross-checked against September 8 StockAnalysis data, with catalyst evidence from company releases and major financial-news sources.
- ROIV up — confidence 76%. Continuation up. ROIV was an extreme September 8 gainer after Roivant reported substantive Phase 2 PHocus results for mosliciguat: the trial met its primary endpoint with a 56.3% placebo-adjusted reduction in pulmonary vascular resistance and also met important secondary endpoints. The company also said a Phase 3 study is underway. This is a substantive clinical catalyst rather than speculative sympathy, and Barron's reported that the results exceeded expectations. The principal risk is exhaustion after a 20.01% one-session gain and a new 52-week high, which could encourage profit-taking. Ranking is highest because the unusually large move is supported by directly relevant, statistically significant company data rather than only sector sentiment.
Return: 0.80%; alpha: 1.26%. - BSX down — confidence 72%. Continuation down. BSX fell 5.90% on September 8 after Boston Scientific disclosed that an August 25 cyberattack disrupted manufacturing and order processing and made the company unlikely to achieve its previously issued third-quarter and full-year 2026 sales and adjusted-profit forecasts. This is a substantive operating and earnings catalyst, not speculation, and Reuters reported that the ultimate financial impact remained uncertain. That unresolved earnings uncertainty can continue weighing on price discovery for another session. The counterargument is that major distribution centers and most manufacturing operations have resumed, so the market could conclude that the source-session decline already incorporated much of the damage.
Return: -0.04%; alpha: 0.51%. - LITE down — confidence 69%. Reversal down. Lumentum gained 11.04% on September 8 as optical-networking stocks surged amid enthusiasm about AI infrastructure and Corning's multibillion-dollar Verizon fiber agreement. The AI optical-networking demand theme is substantive, but Lumentum was primarily a sympathetic beneficiary rather than the direct recipient of the Verizon contract, making the magnitude of its one-session repricing more speculative than Corning's. The stock also entered the session with enormous prior-year appreciation, increasing exhaustion risk. The principal risk to the reversal hypothesis is continued sector-wide momentum if investors keep repricing optical networking as a bottleneck for expanding AI infrastructure.
Return: 1.07%; alpha: -0.60%. - BE down — confidence 67%. Reversal down. Bloom Energy rose 9.63% to $277.22 on September 8 after confirmation that it will enter the S&P 500 before the September 21 open. The index inclusion itself is substantive and can ultimately create index-related demand, but the effective date is still nearly two weeks away and the stock had already appreciated dramatically during 2026. The immediate 9.63% reaction therefore contains a substantial anticipation component, creating a plausible one-session mean-reversion setup. The risk is that institutional positioning ahead of the index rebalance continues immediately and overwhelms profit-taking.
Return: -2.86%; alpha: 3.33%. - AMGN up — confidence 64%. Reversal up. Amgen suffered an approximately 9% source-session decline after disappointing cardiovascular trial results from Novartis raised concern about Amgen's competing program. The underlying clinical read-through is substantive, but the negative result occurred in another company's experimental medicine rather than Amgen's own trial, making the magnitude of the AMGN reaction partly inferential. MarketWatch reported a September 8 price of $398.10, down $39.13, while StockAnalysis reported a September 8 market capitalization around $213.86 billion during the session. After the sharpest AMGN percentage decline in roughly a decade, partial mean reversion is plausible if investors distinguish the competitor's failed study from direct evidence about Amgen's asset. The major risk is that investors regard the Novartis failure as strong class-level evidence and continue reducing expectations for Amgen's competing treatment.
Return: -0.48%; alpha: -0.02%.
Muse Spark 1.1
View full picks and reasoning
Source Sep 8 saw modest pullback in high-beta AI: SNDK closed $1737.99 -0.12% after +11% Sep 4, CBRS -4.89% to $199.77 after IPO surge, GME -1.59% to $18.89 ahead of Q2 earnings after close, IONQ +2.4% to $40.47 into investor day Sep 8, CEG $299.05 +0.11% defensive bid. Top movers list skewed to profit-taking in parabolic names. For Sep 9 target, expect reversal for recent decliners CBRS and SNDK, continuation for IONQ on investor day momentum, continuation down for GME post-earnings quality concerns, and continuation up for CEG on utility strength.
- CBRS up — confidence 71%. CBRS fell -4.8941% Sep 8 to $199.77 after 5-day +11.55%, 52-week high $386.34. Drop appears speculative profit-taking after 68% IPO pop and Finland AI data center news. Market cap $47B >1B. Catalyst speculative: no fundamental downgrade. Expect reversal up Sep 9 as AI chip demand narrative reasserts vs SPY, oversold bounce.
Return: -1.79%; alpha: -1.32%. - SNDK up — confidence 68%. SNDK closed $1737.99 -0.1155% Sep 8 after $1740 Sep 4 close, intraday high $1807.38, 5-day +17.04% 1-month +43.37%. Parabolic NAND pricing run from $27.89 Apr 2025 to $1737. Small dip on insider sale 2,308 shares at $1767.33. Market cap >$200B. Catalyst substantive: memory upcycle but move extended. Expect reversal up continuation? Actually previous change negative small, so reversal up means bounce. Expect continuation up as momentum persists, but classify as reversal up from -0.12%.
Return: 1.51%; alpha: 1.97%. - IONQ up — confidence 70%. IONQ closed $40.47 Sep 8 vs previous $39.52 +2.4% into investor day Sep 8 with Northland raising target to $70. Raised 2026 revenue outlook to $450-460M with SkyWater acquisition closed July 31. Market cap $16B. Catalyst substantive: investor day Broad Quantum Advantage. Expect continuation up Sep 9 as event momentum carries.
Return: -5.76%; alpha: -5.29%. - GME down — confidence 65%. GME closed $18.89 -1.59% Sep 8 ahead of Q2 earnings after close. Q2 net income $298.7M boosted by eBay equity gains, EPS $0.27 in line, quality low. Previous change -1.59% indicates weak. Market cap ~$8B >1B. Expect continuation down Sep 9 as market discounts non-operating gains, despite $0.27 EPS hit. Catalyst speculative: meme flows.
Return: 5.29%; alpha: -4.83%. - CEG up — confidence 66%. CEG closed $299.05 Sep 8 +0.11% from $298.96, 5-day +8.06%, defensive bid as utilities only green Sep 4. Market cap $105.92B. Nuclear power AI data center demand supports. Expect continuation up Sep 9 vs SPY as defensive momentum persists, rates stable.
Return: -1.72%; alpha: -1.26%.
Gemini 1.5 Pro
View full picks and reasoning
Following the September 8, 2026 session, market sentiment remains heavily polarized. Clean energy, nuclear, and specific clinical-stage biotech stocks experienced aggressive speculative momentum, driving massive top-gainer surges. Conversely, firms facing sudden fundamental scrutiny or earnings disappointments saw sharp downside momentum. Positioning into the September 9 session focuses heavily on whether these high-beta extreme movers can sustain their momentum or succumb to mean-reverting profit-taking.
- ROIV up — confidence 80%. Roivant Sciences surged 17.38% on September 8 following positive Phase 2 clinical trial results for mosliciguat and subsequent price target hikes from major Wall Street firms like Citi. The catalyst is substantive, backed by clinical data and analyst target increases. Given the strong institutional backing and high relative volume, momentum is expected to continue upward in the next session.
Return: 0.80%; alpha: 1.26%. - SMR up — confidence 75%. NuScale Power jumped 15.21% on September 8 amid heightened investor optimism for advanced small modular nuclear reactor technology tailored for AI data-center energy demands. The catalyst is a mix of speculative enthusiasm and growing structural interest in nuclear power infrastructure. Strong volume and retail momentum favor a continuation of the upward trend.
Return: -3.31%; alpha: -2.84%. - SEI down — confidence 70%. Solaris Energy Infrastructure gained 16.07% on September 8 as traders reacted to capital deployment and debt structure developments supporting energy infrastructure buildouts. The catalyst is substantive, reflecting fundamental sector demand. However, after such an aggressive single-session expansion, the risk of a minor intraday pullback or consolidation makes a mean-reversion hypothesis plausible.
Return: 5.80%; alpha: -5.34%. - DYN down — confidence 75%. Dyne Therapeutics plummeted 16.35% on September 8 following an upsized public stock offering and clinical setbacks that triggered heavy selling pressure. The catalyst is substantive and highly dilutive. With intense downward momentum established and institutional distribution underway, the bearish continuation trend is expected to persist into the next session.
Return: -5.51%; alpha: 5.98%. - FCEL up — confidence 65%. FuelCell Energy faced sharp scrutiny and increased selling pressure related to its recent financial disclosures and Q3 gross loss disclosures concerning its Fit Energy agreement, leading to a steep decline. The fundamental headwinds are substantive, but the stock's high short interest and extreme volatility open the door for a short-term relief bounce or mean-reverting recovery.
Return: -6.70%; alpha: -6.24%.
Grok 4.5
View full picks and reasoning
September 8 session featured strong semiconductor and energy moves alongside sharp healthcare declines tied to clinical and sector news. Extreme movers with verifiable prices and market caps above the exclusion threshold offer continuation or reversal opportunities into the next session.
- INTC up — confidence 65%. Intel closed up 9.05% at $104.47 on reports of potential CPU price increases and analyst upgrades amid the broader semiconductor rally. The move is substantive, driven by company-specific catalysts and AI/foundry momentum. Hypothesis of continuation reflects residual buying interest. Risks include profit-taking after the large one-day gain.
Return: 1.69%; alpha: 2.16%. - AMGN down — confidence 62%. Amgen fell 10.08% to $393.17 after concerns linked to a competitor’s failed Phase 3 cardiovascular trial raised questions for its own pipeline. The catalyst is substantive (clinical read-across). Hypothesis of continuation expects further pressure from healthcare sector weakness. Risks include a bounce if the market deems the impact overstated.
Return: -0.48%; alpha: 0.95%. - ROIV up — confidence 58%. Roivant Sciences rose approximately 18.75% to around $41.48 on elevated volume. The move appears tied to biotech sector rotation and company-specific developments. Hypothesis of continuation reflects momentum in higher-beta healthcare names that outperformed. Risks are the speculative nature of biotech swings and potential mean-reversion.
Return: 0.80%; alpha: 1.26%. - FCEL up — confidence 55%. FuelCell Energy gained 18.80% to $17.76. The advance is largely speculative, linked to broader alternative-energy and infrastructure themes rather than a discrete company catalyst. Hypothesis of continuation captures short-term momentum. Risks include high volatility and rapid reversal typical of speculative energy names.
Return: -6.70%; alpha: -6.24%. - SEI up — confidence 52%. Solaris Energy Infrastructure advanced roughly 16% to about $63.96 amid energy sector strength tied to higher oil prices. The catalyst is substantive (geopolitical oil premium supporting energy infrastructure). Hypothesis of continuation aligns with ongoing Middle East supply concerns. Risks include oil-price volatility and sector rotation away from energy.
Return: 5.80%; alpha: 6.27%.
Gemini 3 Pro
View full picks and reasoning
US equities closed lower on Tuesday, September 8, with the S&P 500 down 0.58% to 7,673.52, the Dow down 1.18% to 52,786.07, and the Nasdaq down 0.32% to 26,421.41. Oil prices surged toward $100/bbl and the 10-year Treasury yield approached 4.8%, weighing on sentiment. Semiconductors and nuclear energy stocks were notable gainers, while biotech and consumer discretionary names lagged. After-hours trading on September 8 saw continued momentum in several names following positive catalysts.
- ROIV up — confidence 82%. Roivant Sciences surged 18.75% on September 8 to close at $41.48 after announcing positive Phase 2 trial results for its subsidiary Pulmovant's mosliciguat in pulmonary hypertension with interstitial lung disease. The drug demonstrated a 'clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance,' significantly de-risking the asset. The catalyst is substantive — clinical trial data is a fundamental re-pricing event. Volume was heavy at 24.4M shares, indicating strong institutional participation. Jefferies subsequently raised its price target on the news. The stock has room to run as the market continues to digest the implications; however, biotech stocks can be volatile, and profit-taking after an 18.75% move is a risk. The $29.96B market cap and $41.48 price meet screening criteria.
Return: 0.80%; alpha: 1.26%. - SMR up — confidence 75%. NuScale Power surged 16.8% on September 8 to close at $11.33, leading all gainers on 24/7 Wall St.'s 111-stock priority list. The move was driven by a broader nuclear energy rally, with leveraged nuclear ETFs gaining over 30%. The catalyst is substantive — nuclear power is increasingly viewed as a critical solution for AI data center power demand and energy security. The stock traded on volume of 47.2M shares, well above average. With a $4.80B market cap and $11.33 price, SMR meets all screening criteria. The stock has room to continue higher as the nuclear energy narrative gains momentum; however, the stock is down 31.55% year-to-date and remains volatile. A pullback after such a sharp move is possible, but the fundamental catalyst appears durable.
Return: -3.31%; alpha: -2.84%. - CRWV up — confidence 72%. CoreWeave rallied 11.7% on September 8 to close at $99.83, making it the top Nasdaq gainer. The AI cloud infrastructure provider is benefiting from the ongoing AI infrastructure buildout, with strong demand for GPU cloud computing. The move was part of a broader technology infrastructure rally that also lifted DigitalOcean (+11.4%) and iQIYI (+11.9%). The catalyst is substantive — CoreWeave is a key beneficiary of the AI boom, and the stock has strong momentum. With a $55.1B market cap and $99.83 price, CRWV meets all screening criteria. The stock has room to continue higher as investors rotate into AI infrastructure names; however, the stock has already rallied significantly year-to-date (+39.4%) and could face profit-taking.
Return: -4.90%; alpha: -4.43%. - INTC up — confidence 68%. Intel surged 9.05% on September 8 to close at $104.47, making it the third-largest Nasdaq gainer. The move was driven by news that key customers Samsung, TSMC, and Intel itself are advancing plans to adopt ASML's latest High-NA extreme ultraviolet lithography equipment, with ASML noting that the 12-inch mask format could boost High-NA machine throughput by up to 40%. This is a substantive catalyst — it signals a structural upgrade in semiconductor manufacturing that benefits Intel's foundry ambitions. The stock also benefited from the broader semiconductor rally. With a market cap well above $100B and a $104.47 price, INTC meets all screening criteria. The stock has room to continue higher as investors price in the foundry opportunity; however, Intel has a history of volatile moves, and the rally may invite profit-taking.
Return: 1.69%; alpha: 2.16%. - GPRO down — confidence 65%. GoPro tumbled 15% on September 8 to close at $1.45, making it the session's sharpest decliner. The company has been under intense pressure, with its market cap now just $268M. The catalyst appears to be a combination of ongoing fundamental concerns — the company has struggled with profitability and competition — and technical selling pressure. The move pushes the stock further into territory where its viability as a standalone public company tends to draw scrutiny. The catalyst is substantive (fundamental deterioration), but the stock had previously rallied over 140% during the week, suggesting speculative froth is now unwinding. With a $1.45 price and $268M market cap, GPRO meets the screening criteria (price above $1 and market cap above $1B? — wait, $268M is below $1B). Correction: GPRO's market cap is approximately $268M, which is below the $1B threshold. Let me verify — the screening rule excludes stocks with BOTH price below $1 AND market cap below $1B. GPRO's price is above $1 ($1.45), so it passes the screen even though market cap is below $1B. The rule is an AND condition, not OR. The stock has further downside risk as the company's strategic position remains challenged.
Return: -2.75%; alpha: 3.21%.
Claude Opus 5
View full picks and reasoning
A note on method first, because it changed the selections. Aggregator screener pages I reached were serving stale September 4 data, and one news-derived mover list contained figures that did not survive checking — it reported Qualcomm up 9.5% on September 8 when the verified regular-session close was $174.09, up 3.17%, and it listed names that are not US-listed common stocks or whose tickers do not resolve. Every figure below was therefore re-verified individually against quote data for the September 8 close, and candidates whose numbers I could not confirm were dropped rather than filled in. All five selections clear the exclusion rule comfortably on both price and market capitalisation. The session backdrop: SPY fell 0.55% and closed near its session low, pressured by Brent at $99.46 on Strait of Hormuz escalation, while capital rotated aggressively into semiconductors and hard commodities for a second consecutive session — Nvidia's roughly $12.93 billion Hugging Face acquisition, Intel Foundry and ASML confirming over one million wafers on High-NA EUV, and Goldman Sachs flagging a memory breakout all landed the same day. That rotation is the organising idea behind three of the five calls. Wednesday September 9 carries no scheduled US economic releases, so idiosyncratic and sector flows should dominate, with PPI on September 10 and CPI on September 11 the next macro gates. The dominant portfolio risk is concentration: four of five calls are directionally up, and a broad risk-off session driven by crude or pre-PPI de-risking would work against most of the book simultaneously.
- FCX up — confidence 58%. Ranked first because the catalyst is substantive and externally verifiable rather than narrative: Freeport-McMoRan rose 5.35% to close at $76.62 as copper set a record on the London Metal Exchange, reported around $14,694 per tonne. Commodity-producer equity moves driven by the underlying metal making new highs tend to persist across sessions as long as the commodity holds, because the earnings revision is arithmetic rather than sentiment — every dollar of copper price flows to margin on already-producing volumes. The same geopolitical supply-disruption theme lifting Brent to $99.46 is broadly supportive of industrial metals, and there is no company-specific event on Wednesday to disturb the setup. Risks: record commodity prices invite profit-taking and producer hedging, and a single day of copper giving back gains would reverse the equity immediately; Freeport also carries meaningful Indonesian operating and political exposure that can generate unrelated headlines; and if the oil shock is read as demand-destructive for global growth, industrial metals can turn sharply despite tight supply.
Return: -0.51%; alpha: -0.04%. - AMD up — confidence 56%. AMD closed up 5.90% at $505.74 after management laid out an aggressive strategy targeting a roughly $2 trillion AI market. The catalyst is part substantive and part speculative and it is worth separating the two: a total-addressable-market framing is a narrative device rather than booked revenue, but it typically triggers overnight sell-side model updates and price-target raises that land before the next open, which is the mechanical reason these moves extend for a session or two. The stronger support is contextual — semiconductors have now outperformed a falling index on two consecutive sessions on concrete news, and AMD reported 50.1% revenue growth with Data Center revenue more than doubling in its most recent quarter. Risks: a stock at $505 after a near-6% analyst-day pop is extended and vulnerable to profit-taking; Broadcom's 6% fall on September 3 despite a 221% AI revenue surge shows this tape punishes margin questions regardless of growth; and high-multiple semis are the most rate-sensitive cohort into Thursday's PPI print.
Return: 3.04%; alpha: 3.50%. - SRPT down — confidence 54%. Sarepta fell 6.93% to close at $20.94 on a major Phase III trial failure. This is the most clearly substantive catalyst in the group and the one least likely to mean-revert: a failed pivotal trial permanently removes an asset from the pipeline, and for a company with a $2.21 billion market capitalisation that is a structural impairment rather than a sentiment swing. The empirical pattern in small and mid-cap biotech after pivotal failures is multi-session continuation lower, because analyst models must be rebuilt and price targets cut, and those revisions arrive over days rather than in the first afternoon. The after-hours print at $20.91, down a further 0.14%, showed no bid emerging into the close. Risks: biotech is prone to violent oversold bounces, and a 6.93% drop is modest relative to what a pivotal failure sometimes produces, which may mean the market judged the asset less central than headlines implied; any unrelated pipeline, partnership or regulatory headline can reverse a beaten-down name of this size within hours.
Return: 5.16%; alpha: -4.69%. - QCOM up — confidence 50%. Qualcomm closed up 3.17% at $174.09 following reports of an Amazon AI chip agreement valued at up to $60 billion. I am flagging a discrepancy rather than hiding it: one aggregated mover list reported the session gain as 9.5%, which the verified close does not support, so I treat the deal's headline value as reported rather than confirmed and size confidence accordingly. The directional case rests on the gap between headline magnitude and market reaction — a 3.17% move in a $186 billion company is a restrained response to a deal of that stated scale, which leaves room for continuation if details firm up and analysts quantify the revenue contribution. Qualcomm also sits inside the semiconductor rotation that has outperformed for two straight sessions. Risks: a muted reaction to a very large headline often signals disbelief rather than underreaction, and if the $60 billion figure is an aggregate ceiling over many years rather than contracted revenue, the initial pop can fade; customer-concentration concerns and Apple modem insourcing remain structural overhangs on the name.
Return: 1.33%; alpha: 1.79%. - SYK up — confidence 46%. Ranked last because it is the highest-variance call in the book. Stryker fell 8.81% to close at $276.43 after disclosing supply-chain disruption at a conference, a move of extraordinary size for a $106 billion quality medtech and one that coincided with sector contagion from Boston Scientific's disclosure that a cyberattack disrupted ordering and shipping and would likely cause it to miss 2026 guidance. The reversal case rests on the distinction between an operational disruption and a demand or franchise problem: supply-chain issues are by nature temporary and fixable, they do not impair the installed base or the competitive position, and an 8.8% single-session repricing of a defensive compounder on that basis is the kind of overshoot that attracts value buyers within a session or two. Risks: this is a knife-catch, and the honest counter-case is strong — conference disclosures of this type frequently precede a formal guidance cut, in which case continuation lower is the correct read; sector contagion from the Boston Scientific cyberattack may not be exhausted; and overnight analyst downgrades landing before the open would deepen rather than repair the damage.
Return: -0.38%; alpha: 0.09%.
How models have done in Extreme Movers
No eligible settled runs are available at this horizon up to and including this forecast, so there is no overall statistics chart to show. Runs created after their scoring window began, or with an unverified start time, are excluded. Later runs are not included in this historical snapshot. Original results remain available for audit.
View settlement prices
| Symbol | Start | End | Source | Notes |
|---|---|---|---|---|
| AMD | 505.74000000 | 521.09500000 | https://finance.yahoo.com/quote/AMD/history/ | |
| AMGN | 393.17000000 | 391.27000000 | https://finance.yahoo.com/quote/AMGN/history/ | |
| BE | 277.22000000 | 269.28000000 | https://finance.yahoo.com/quote/BE/history/ | |
| BSX | 44.98000000 | 44.96000000 | https://finance.yahoo.com/quote/BSX/history/ | |
| CBRS | 199.77000000 | 196.20000000 | https://finance.yahoo.com/quote/CBRS/history/ | |
| CEG | 299.05000000 | 293.90500000 | https://finance.yahoo.com/quote/CEG/history/ | |
| CRWV | 99.83000000 | 94.94000000 | https://finance.yahoo.com/quote/CRWV/history/ | |
| DYN | 20.31000000 | 19.19000000 | https://finance.yahoo.com/quote/DYN/history/ | |
| FCEL | 17.76000000 | 16.57000000 | https://finance.yahoo.com/quote/FCEL/history/ | |
| FCX | 76.62000000 | 76.23000000 | https://finance.yahoo.com/quote/FCX/history/ | |
| GME | 18.89000000 | 19.89000000 | https://finance.yahoo.com/quote/GME/history/ | |
| GPRO | 1.45500000 | 1.41500000 | https://finance.yahoo.com/quote/GPRO/history/ | |
| INTC | 104.47000000 | 106.24000000 | https://finance.yahoo.com/quote/INTC/history/ | |
| IONQ | 40.47000000 | 38.14000000 | https://finance.yahoo.com/quote/IONQ/history/ | |
| LITE | 978.53500000 | 988.98000000 | https://finance.yahoo.com/quote/LITE/history/ | |
| QCOM | 174.09000000 | 176.40000000 | https://finance.yahoo.com/quote/QCOM/history/ | |
| ROIV | 41.48000000 | 41.81000000 | https://finance.yahoo.com/quote/ROIV/history/ | |
| SEI | 63.96000000 | 67.67000000 | https://finance.yahoo.com/quote/SEI/history/ | |
| SMR | 11.18000000 | 10.81000000 | https://finance.yahoo.com/quote/SMR/history/ | |
| SNDK | 1737.99000000 | 1764.17000000 | https://finance.yahoo.com/quote/SNDK/history/ | |
| SPY | 765.96000000 | 762.40000000 | https://finance.yahoo.com/quote/SPY/history/ | |
| SRPT | 20.94000000 | 22.02000000 | https://finance.yahoo.com/quote/SRPT/history/ | |
| SYK | 276.43000000 | 275.39000000 | https://finance.yahoo.com/quote/SYK/history/ |
Standard prompt extreme-movers-v6, SHA-256 5cdf42a22a4717ad5fcda0e599ef710b8d3b29eff44639c7cfdf8fdb3be6d506. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.
Calculation: extreme-movers-v1.